When online weight-loss drugs are too good to be true
A telehealth company partnered with a pharmacy that lacked a required license, raising doubts about the safety and efficacy ...
Zepbound for Weight Loss: What to Know About This Weight Loss Drug
For years, conventional wisdom has been that weight loss is a matter of willpower. Those who are overweight or obese just need to try harder to eat less and exercise more. But while diet and ...
Dr Boreham’s Crucible: On a dream run, this biotech shows no sign of dozing on the job
Resmed has its origins in the 1980s, when Sydney sleep expert Dr Colin Sullivan converted a vacuum cleaner to deal with the ...
pharmaphorum16d
Zepbound tops Wegovy in first head-to-head weight-loss trial
Eli Lilly is playing catch-up to Novo ... The results of the first head-to-head trial of Lilly's dual GLP-1/GIP agonist Zepbound (tirzepatide) and Novo Nordisk's GLP-1 agonist Wegovy (semaglutide ...
Yahoo Finance16d
With Zepbound Not Matching Expectations, Should Investors Give Up on Eli Lilly?
In a recent press release, Eli Lilly's management said that the U.S. incretin market, which includes drugs like Zepbound and Mounjaro, didn't grow as fast as it anticipated in the fourth quarter.
ResMed Inc. (NYSE:RMD) Q2 2025 Earnings Call Transcript
Q2 2025 Earnings Call Transcript January 30, 2025 ResMed Inc. beats earnings expectations. Reported EPS is $2.43, expectations were $2.32. Operator: Welcome to the Q2 Fiscal Year 2025 ResMed Earnings ...
ResMed beats quarterly profit estimates on demand for sleep disorder devices
ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder. ResMed makes continuous positive ...